ENXTPA:NANO

Stock Analysis Report

Executive Summary

Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Nanobiotix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-16.9%

NANO

-8.0%

FR Biotechs

2.9%

FR Market


1 Year Return

-56.6%

NANO

-41.1%

FR Biotechs

10.2%

FR Market

Return vs Industry: NANO underperformed the French Biotechs industry which returned -41.1% over the past year.

Return vs Market: NANO underperformed the French Market which returned 10.2% over the past year.


Share holder returns

NANOIndustryMarket
7 Day-16.9%-8.0%2.9%
30 Day-30.0%-15.6%-0.3%
90 Day-33.2%-21.9%0.2%
1 Year-56.6%-56.6%-41.0%-41.1%14.0%10.2%
3 Year-58.1%-58.1%-61.3%-61.3%44.3%30.4%
5 Year-62.9%-62.9%-61.5%-60.3%75.2%49.3%

Price Volatility Vs. Market

How volatile is Nanobiotix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nanobiotix undervalued based on future cash flows and its price relative to the stock market?

6.89x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: NANO (€6.39) is trading above our estimate of fair value (€0.05)

Significantly Undervalued: NANO is trading above our estimate of fair value.


Price Based on Earnings

PE vs Industry: NANO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NANO is unprofitable, so we can't compare its PE Ratio to the French market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate NANO's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: NANO is overvalued based on its PB Ratio (6.9x) compared to the FR Biotechs industry average (2x).


Next Steps

Future Growth

How is Nanobiotix expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

-8.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: NANO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NANO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NANO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NANO's revenue (61.3% per year) is forecast to grow faster than the French market (4.5% per year).

High Growth Revenue: NANO's revenue (61.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if NANO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Nanobiotix performed over the past 5 years?

-26.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NANO is unprofitable, and losses have increased over the past 5 years at a rate of -26% per year.

Accelerating Growth: Unable to compare NANO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NANO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: NANO has a negative Return on Equity (-200.88%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NANO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NANO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Nanobiotix's financial position?


Financial Position Analysis

Short Term Liabilities: NANO's short term assets (€59.8M) exceeds its short term liabilities (€12.4M)

Long Term Liabilities: NANO's short term assets (€59.8M) exceeds its long term liabilities (€42.2M)


Debt to Equity History and Analysis

Debt Level: NANO's debt to equity ratio (178.7%) is considered high

Reducing Debt: NANO's debt to equity ratio has increased from 5.2% to 178.7% over the past 5 years.


Balance Sheet

Inventory Level: NANO has a low level of unsold assets or inventory.

Debt Coverage by Assets: NANO's debt is covered by short term assets (assets are 1.614140x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NANO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NANO has sufficient cash runway for 1.214084 years if free cash flow continues to reduce at historical rates of -18.5% each year.


Next Steps

Dividend

What is Nanobiotix's current dividend yield, its reliability and sustainability?

0.078%

Expected Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.6%markettop25%4.6%industryaverage1.2%forecastin3Years0.08%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate NANO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NANO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NANO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NANO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NANO's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

What is the CEO of Nanobiotix's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Laurent Lévy (46yo)

0yrs

Tenure

€1,427,080

Compensation

Mr. Laurent Lévy, Ph.D. serves as the President of the Executive Board and Chief Executive Officer of Nanobiotix SA at Valbiotis SAS. Mr. Lévy co-founded Nanobiotix SA in 2003. Mr. Lévy has a thorough unde ...


CEO Compensation Analysis

Compensation vs. Market: Laurent's total compensation ($USD1.58M) is above average for companies of similar size in the French market ($USD352.07K).

Compensation vs Earnings: Laurent's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.8yrs

Average Tenure

64yo

Average Age

Experienced Management: NANO's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

6.2yrs

Average Tenure

58yo

Average Age

Experienced Board: NANO's board of directors are considered experienced (6.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Para Prasad (74yo)

    Co-Founder and Member of Scientific Board

    • Tenure: 0yrs
  • Laurent Lévy (46yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: €1.43m
  • Earl Bergey (64yo)

    Co-Founder

    • Tenure: 16.8yrs
  • Elsa Borghi

    Head of Innovation and Drug Discovery

    • Tenure: 0yrs
    • Compensation: €723.42k
  • Philippe Mauberna

    Chief Financial & Administrative Officer and Member of the Executive Board

    • Tenure: 0yrs
    • Compensation: €949.41k
  • Noël Kurdi

    Director of Investor Relations

    • Tenure: 3yrs
  • Edwina Baskin-Bey

    Chief Medical Officer & Member of Executive Board

    • Tenure: 0.3yrs
  • Alain Dostie

    Chief Operating Officer

    • Tenure: 2.7yrs
  • Anne-Juliette Hermant

    Chief People Officer (CPO) & Member of Executive Board

    • Tenure: 0.3yrs
  • Brandon Owens

    VP of Strategic Marketing & Corporate Communication

    • Tenure: 0yrs

Board Members

  • Enno Spillner (49yo)

    Member of Supervisory Board

    • Tenure: 5.8yrs
    • Compensation: €14.29k
  • Christophe Douat (53yo)

    Member of Supervisory Board

    • Tenure: 8.8yrs
    • Compensation: €10.71k
  • Michel Marty

    Member of Scientific Board

    • Tenure: 0yrs
  • Laurent Condomine

    Chairman of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €21.43k
  • Para Prasad (74yo)

    Co-Founder and Member of Scientific Board

    • Tenure: 0yrs
  • Jean Claude

    Member of Scientific Board

    • Tenure: 0yrs
  • Alain Herrera (69yo)

    Member of Supervisory Board

    • Tenure: 6.7yrs
    • Compensation: €70.71k
  • Anne-Marie Graffin (58yo)

    Independent Member of The Supervisory Board

    • Tenure: 5.8yrs
    • Compensation: €12.86k

Company Information

Nanobiotix S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nanobiotix S.A.
  • Ticker: NANO
  • Exchange: ENXTPA
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €142.796m
  • Shares outstanding: 22.35m
  • Website: https://www.nanobiotix.com

Number of Employees


Location

  • Nanobiotix S.A.
  • 60 rue de Wattignies
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NANOENXTPA (Euronext Paris)YesOrdinary SharesFREUROct 2012
0QAVLSE (London Stock Exchange)YesOrdinary SharesGBEUROct 2012
NANOPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEUROct 2012
5NRDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2012

Biography

Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnif ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 22:46
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)